We investigated whether differences in cell morphology and size can enable irreversible electroporation (IRE) to have greater cytotoxicity to cancer cells than Chimeric Antigen Receptor (CAR) T cells. IRE was performed on murine (AE17) and human cancer cell lines (MGM and MSTO), and CAR T cells by varying applied voltage, pulse width and pulse numbers in 4-mm gap cuvettes. Treatment parameters showing greatest differential cytotoxicity between cancer and CAR T cells was further tested with IRE performed in a 3D tumor mimic. Confocal microscopy with fluorescent staining for cytoplasm, nucleus, cell death and viability were used to extract cell morphology and spatial extent of IRE. Cell survival and proliferation was quantified at 24 hours post-IRE for all studies. Function of IRE treated, and control CAR T cells was compared with a 51Cr release assay at increasing effector to target ratio. Comsol simulations were used to model electric field gradient in tumor mimic, induced transmembrane voltage for different cell types, and statistical probability of cell death from IRE. Simulations models reconstructed using confocal imaging indicated that cancer cells develop a transmembrane potential that is 1.5 – 2-fold higher than T cells when exposed to the same electric field, increasing their susceptibility for membrane permeabilization. Pulse parameter (1000 V/cm, 20 μs pulse width, 200 pulses) yielding maximum differential cytotoxicity (MSTO: 1.7±0.7% vs. CAR T cell: 61.8 ± 6.6%, P < 0.01) was validated in the 3D tumor mimic (MSTO: 52% vs. CAR T cell: 88% viability on flow cytometry), where we found IRE did not alter the proliferation of CAR T cells or effector function measured with the 51Cr release assay (p not significant). Simulation models of 3D tumor mimic allowed estimation of electric field gradient in vitro along with estimation of relative cell viability as a function of distance from the electrodes based on the statistical models. Simulation-guided and experimental optimization of electric pulse parameters enable IRE with greater cytotoxicity to cancer cells than CAR T cells, increasing the effector to target ratio in the tumor microenvironment.